Distributor inventory | Tablet

Type 2 diabetes mellitus (to improve glycaemic control along with diet and exercise); may be used with other antidiabetic medicines as prescribed.

Empagliflozin is an SGLT2 inhibitor that reduces glucose reabsorption in the kidneys. It increases urinary glucose excretion, thereby lowering blood glucose and causing mild diuresis.

Tablet for oral use. Take once daily as prescribed, preferably at the same time each day, with or without food. Swallow whole with water; do not crush/chew. Maintain adequate hydration.

Increased urination, thirst, urinary tract infection, genital fungal infection (vulvovaginitis/balanitis), dizziness, low blood pressure, hypoglycaemia (when used with insulin or sulfonylureas), nausea

Not for type 1 diabetes; risk of diabetic ketoacidosis (can occur even with near-normal glucose)—seek urgent care for nausea/vomiting, abdominal pain, rapid breathing. Can cause dehydration and hypotension, especially in elderly, on diuretics, or with low BP; maintain fluids. Monitor kidney function; avoid/initiate with caution in renal impairment as per clinician advice. Higher risk of genital mycotic infections and UTIs; maintain hygiene and report symptoms. Temporarily withhold before major surgery/acute serious illness or prolonged fasting to reduce DKA risk. Use caution in patients with history of ketoacidosis.

Diuretics (increased dehydration/hypotension risk), insulin and sulfonylureas (increased hypoglycaemia risk), ACE inhibitors/ARBs and other antihypertensives (additive BP lowering), NSAIDs (may worsen renal function in predisposed), lithium (levels may change with diuresis)

Store below 25°C in a dry place, protected from moisture and light. Keep in original blister pack and out of reach of children.

Jardiance 25 Tablet, Empa 25 Tablet, Empagliflozin 25 mg Tablet (generic), Glyxambi 25/5 Tablet (empagliflozin+linagliptin), Synjardy 25/1000 Tablet (empagliflozin+metformin)